196 related articles for article (PubMed ID: 17992596)
1. The future of biologic agents in the treatment of Sjögren's syndrome.
Meijer JM; Pijpe J; Bootsma H; Vissink A; Kallenberg CG
Clin Rev Allergy Immunol; 2007 Jun; 32(3):292-7. PubMed ID: 17992596
[TBL] [Abstract][Full Text] [Related]
2. Present and future of biologic drugs in primary Sjögren's syndrome.
Sambataro D; Sambataro G; Dal Bosco Y; Polosa R
Expert Opin Biol Ther; 2017 Jan; 17(1):63-75. PubMed ID: 27616561
[TBL] [Abstract][Full Text] [Related]
3. Biologic treatment in Sjögren's syndrome.
Sada PR; Isenberg D; Ciurtin C
Rheumatology (Oxford); 2015 Feb; 54(2):219-30. PubMed ID: 25342375
[TBL] [Abstract][Full Text] [Related]
4. World Workshop on Oral Medicine VII: Immunobiologics for salivary gland disease in Sjögren's syndrome: A systematic review.
Gueiros LA; France K; Posey R; Mays JW; Carey B; Sollecito TP; Setterfield J; Woo SB; Culton D; Payne AS; Lodi G; Greenberg MS; De Rossi S
Oral Dis; 2019 Jun; 25 Suppl 1(Suppl 1):102-110. PubMed ID: 31140693
[TBL] [Abstract][Full Text] [Related]
5. Biologic therapy in Sjögren's syndrome.
Shao Q
Clin Rheumatol; 2021 Jun; 40(6):2143-2154. PubMed ID: 33106929
[TBL] [Abstract][Full Text] [Related]
6. [Indications and options of new immune modulatory therapies for Sjögren's syndrome].
Feist E; Dörner T; Hansen A
Z Rheumatol; 2007 Dec; 66(8):679-85. PubMed ID: 17999070
[TBL] [Abstract][Full Text] [Related]
7. Biologic treatments in Sjögren's syndrome.
Bowman S; Barone F
Presse Med; 2012 Sep; 41(9 Pt 2):e495-509. PubMed ID: 22836195
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials.
Gottenberg JE; Dörner T; Bootsma H; Devauchelle-Pensec V; Bowman SJ; Mariette X; Bartz H; Oortgiesen M; Shock A; Koetse W; Galateanu C; Bongardt S; Wegener WA; Goldenberg DM; Meno-Tetang G; Kosutic G; Gordon C
Arthritis Rheumatol; 2018 May; 70(5):763-773. PubMed ID: 29381843
[TBL] [Abstract][Full Text] [Related]
9. New developments in Sjogren's syndrome.
Thalayasingam N; Baldwin K; Judd C; Ng WF
Rheumatology (Oxford); 2021 Dec; 60(Suppl 6):vi53-vi61. PubMed ID: 34951923
[TBL] [Abstract][Full Text] [Related]
10. Clinical and immunological consequences of total glucosides of paeony treatment in Sjögren's syndrome: A randomized controlled pilot trial.
Zhou Y; Jin L; Kong F; Zhang H; Fang X; Chen Z; Wang G; Li X; Li X
Int Immunopharmacol; 2016 Oct; 39():314-319. PubMed ID: 27517517
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
Bowman SJ; Fox R; Dörner T; Mariette X; Papas A; Grader-Beck T; Fisher BA; Barcelos F; De Vita S; Schulze-Koops H; Moots RJ; Junge G; Woznicki JN; Sopala MA; Luo WL; Hueber W
Lancet; 2022 Jan; 399(10320):161-171. PubMed ID: 34861168
[TBL] [Abstract][Full Text] [Related]
12. Cytokines in Sjogren's syndrome: potential therapeutic targets.
Roescher N; Tak PP; Illei GG
Ann Rheum Dis; 2010 Jun; 69(6):945-8. PubMed ID: 20410069
[TBL] [Abstract][Full Text] [Related]
13. Emerging biological therapies in primary Sjogren's syndrome.
Ramos-Casals M; Brito-Zerón P
Rheumatology (Oxford); 2007 Sep; 46(9):1389-96. PubMed ID: 17586555
[TBL] [Abstract][Full Text] [Related]
14. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).
Mariette X; Ravaud P; Steinfeld S; Baron G; Goetz J; Hachulla E; Combe B; Puéchal X; Pennec Y; Sauvezie B; Perdriger A; Hayem G; Janin A; Sibilia J
Arthritis Rheum; 2004 Apr; 50(4):1270-6. PubMed ID: 15077311
[TBL] [Abstract][Full Text] [Related]
15. Use of Biologics in Sjögren's Syndrome.
Nocturne G; Cornec D; Seror R; Mariette X
Rheum Dis Clin North Am; 2016 Aug; 42(3):407-17. PubMed ID: 27431344
[TBL] [Abstract][Full Text] [Related]
16. Biologic therapies in primary Sjögren's syndrome.
Bowman SJ
Curr Pharm Biotechnol; 2012 Aug; 13(10):1997-2008. PubMed ID: 22208654
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Sjögren's syndrome: current therapy and future directions.
Fox RI; Fox CM; Gottenberg JE; Dörner T
Rheumatology (Oxford); 2021 May; 60(5):2066-2074. PubMed ID: 31034046
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study.
De Vita S; Quartuccio L; Seror R; Salvin S; Ravaud P; Fabris M; Nocturne G; Gandolfo S; Isola M; Mariette X
Rheumatology (Oxford); 2015 Dec; 54(12):2249-56. PubMed ID: 26242856
[TBL] [Abstract][Full Text] [Related]
19. Total glucosides of paeony (TGP) alleviates Sjogren's syndrome through inhibiting inflammatory responses in mice.
Li B; Liu G; Liu R; He S; Li X; Huang L; Wang Z; Li Y; Chen Y; Yin H; Fang W
Phytomedicine; 2020 Jun; 71():153203. PubMed ID: 32402913
[TBL] [Abstract][Full Text] [Related]
20. Primary Sjogren's syndrome: current and prospective therapies.
Thanou-Stavraki A; James JA
Semin Arthritis Rheum; 2008 Apr; 37(5):273-92. PubMed ID: 17714766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
